Loading this company
Repligen Corporation
RGENPrices in USD
TickerWorth ScoreF39/100
What we think
Priced above our range of $32.98 to $46.75.
Price
$174.26USD down −$9.91 (−5.38%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 13:48 UTC (4 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 2 models, on today’s numbers
$32.98–$46.75
What the price needs: revenue growth of more than 25%/yr for 5 years (our model assumes 10.1%), or investors accepting a ~3.3% discount rate, vs the 10.1% our model uses.
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Price $174.26Priced · Prices are delayed.
Is it a good business?
- Valuation17 out of 100
- Growth67 out of 100
- Financial health100 out of 100
- Past performance83 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$197.95 across 20 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in United States. The company employs roughly 2,000 people.
Key stats
52-week range$100.99–$198.87
- Open
- $183.81
- Day high
- $185.98
- Day low
- $172.39
- Previous close
- $184.17
- Volume
- 1,213,319 · 1.00× avg
- Average volume
- 1,218,464
- Market cap
- $11,137,479,680.00
- P/E (TTM)
- 240.30
- Earnings per share
- $0.73
- Beta
- 1.08
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Completed an acquisition or sale of assets
- Changed leadership or its board
- Disclosed another material event
- Reported quarterly or annual results
- Signed a material agreement
- Reported shareholder vote results
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Douglass Brian RobbGrant / award · —
- Loeillot OlivierOpen-market sale · $238,273.75
Not investment advice. TickerWorth Score is a model output.